Urology Times staff

“The co-primary end points are safety and overall response rate as measured via RESIST v1.1,” says Jonathan A. Chatzkel, MD.

“Medical oncologists, including academic and in the community, tend to order more genomic testing than urologic oncologists,” says Dalia Kaakour, MD, MS, MPH.

"I think it's very interesting to see that we continue to see a survival benefit at 55-months follow-up," says Maria Teresa Bourlon, MD, MSc, MS.

“It's important to note as well that the kidney cancer biology is really distinct from a lot of other solid tumors, and particularly other immunotherapy response to solid tumors,” says David A. Braun, MD, PhD.

“If you put everything together, the cabo/atezo combination statistically significantly improved the progression-free survival and reduced the risk of progression or death by 35% in a patient population with very poor prognosis,” says Neeraj Agarwal, MD, FACSO.

“This will become a very attractive option if approved by the FDA because the treatment burden on patients will be significantly reduced, thus making it easier for patients to access it,” says Saby George, MD, FACP.

"When we think about germline mutations, I think the number one thing that comes through for many urologists as well as oncologists is Lynch syndrome," says Laura Bukavina, MD, MPH, MSc.

“[It is] reassuring that in patients who had a prior novel hormonal agent, the combination of enzalutamide plus talazoparib is still effective [and] still an effective option,” says Arun Azad, MD.

"[This is] the first time ever since we started conducting randomized phase 3 studies in the adjuvant setting of kidney cancer that we see an overall survival benefit," says Toni K. Choueiri, MD.

"What we saw was it that there were a significant number of patients that did change their management based on the findings. Of those patients, 88% of them changed because of a positive test," says Benjamin H. Lowentritt, MD, FACS.

Andrea B. Apolo, MD, shares key interim findings from the AMBASSADOR Alliance trial.

“We're really looking at a situation where most of the HRR testing is happening when patients have already exhausted all other standard options,” says Daniel J. George, MD.

"The key end points were observed response rate in the overall cohort, progression-free and overall survival from EV start in the overall cohort, and as an exploratory end point, overall survival from platinum-based chemotherapy start in the overall cohort," says Amanda Nizam, MD.

"What ARASTEP is asking is how effective of a biomarker is PSMA PET/CT?" says Alexander M. Chehrazi-Raffle, MD.

"What we found is that there was rapid adoption and uptake of PSMA PET almost immediately after these agents were first approved in the United States," says Michael S. Leapman, MD, MHS.

"These data really show that even in the patients who upgrade and have more severe disease than were initially expected, even if their surgery was delayed for 12 months after having this upgraded diagnosis, these patients did just as well from a recurrence perspective, compared to patients who got surgery right away," says Kevin Shee, MD, PhD.

"From a physician standpoint, [telemedicine] allows you to have a greater reach of patients that you can help, that you can educate, that you can help improve their quality of life," says Helen L. Bernie, DO, MPH.

"In general, the majority of patients were very satisfied with the treatment," says Nitya E. Abraham, MD.

"Many men are quite reluctant to go to a specialist, specifically the urologist, because of the fear or reluctance to undergo an invasive test, [such as] a rectal exam," says Shahrokh F. Shariat, MD.

“To the point where a child would come in and request to see a cartoon character was really quite interesting for me,” says Patrina H. Y. Caldwell, BMed, FRACP, PhD.

"I think some of the biggest advances have come in the surgical space," says Vikas Desai, MD.

"We investigated and compared the risk of infection after transperineal MRI-targeted biopsy vs a transrectal MRI-targeted biopsy," says Jim C. Hu, MD, MPH.

“I definitely am more careful about who I offer Botox to in men,” says Gina M. Rooker, MD.

"I think that at any point, everyone is somewhere on that spectrum," says Anne M. Suskind, MD, MS, FACS, FPMRS.

"I like to tell my patients, one of the first kind of treatments is actually reassurance," says Miriam Harel, MD.

"I tried to cover the focal therapies, at least just review some of the new ones that are coming in, even though they're still not necessarily 100% mainstream," says Andrew L. Siegel, MD.

"The main finding is that when you look at men with low testosterone, grouped 18 and above, we found that there is an association between low testosterone and kidney stone encounter diagnoses," says Austin Thompson.

“We want to serve as role models for pre-med students to come into the urology field [and] to explore what urology is, because there is a great need not only in general for urologists, but for Hispanic urologists. ,” says Pedro P. Maria, DO.

"In our multivariate analysis, we actually found that there was no significant difference between the groups," says Kevin Shee, MD, PhD.

"There's just a tremendous opportunity for telehealth and being able to increase delivery to patients in these areas or at least reduce their amount of travel time to get to see a urologist based on where they live," says Kara L. Watts, MD.